In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural fragment Cosyntropin | Synthetic analog Melanotan I (afamelanotide) | |
|---|---|---|---|
| Identity | |||
| Kind | Natural fragment | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 97 | 667 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 6 (6 in people) | 36 (29 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 27 · 4 active13 more mention it but do not test it | 23 · 1 active | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Cortrosyn says: “Diagnostic screening of adrenocortical insufficiency in adults and pediatric patients, in combination with other diagnostic tests”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Cosyntropin | Melanotan I (afamelanotide) |
|---|---|---|
| Receptor activity and mechanismReproductive and sexual health | 6222 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Scenesse says: “Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)”
| Adverse eventsWhole body | 55 | 29245 |
|---|
| PainNervous system and cognition | 2121 | 752 |
|---|
| NeuroprotectionNervous system and cognition | 99 | 5423418 |
|---|
| Immune responseImmune and inflammation | 11 | 2631112 |
|---|
| PharmacokineticsPharmacology | 88 | 10631 |
|---|
| Appetite and food intakeMetabolic and weight | 22 | 2525 |
|---|
| Exercise and physical functionNervous system and cognition | 11 | 651 |
|---|
| Bone and jointMusculoskeletal | 33 | 211 |
|---|
| MortalityWhole body | 22 | 11 |
|---|
| Respiratory functionRespiratory | 11 | 44 |
|---|
| Stress hormonesEndocrine and hormones | 312 | 22 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Cosyntropin is the same as Corticotropin residues 1 to 24.
No differences in the aligned region.
Melanotan I (afamelanotide) differs from Alpha-melanocyte-stimulating hormone (alpha-MSH) at 2 positions and carries 2 added groups.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Cosyntropin | Melanotan I (afamelanotide) |
|---|---|---|
| PainMusculoskeletalCompared as: value in the arm that got the peptide, in % | 91% Epidural blood patch rate Placebo group: 86% Dose studied: 1 mgsingle dosen = 442025 | No randomized trial result 7 results from other study designs. |
| Adverse eventsInfectionCompared as: value in the arm that got the peptide, in % | 5% Secondary effects Dose studied: 3 mg on D1 and 2 mg/d on D2 and D33 daysn = 1021989 | No comparable result 7 randomized-trial results measure it in another way or another unit. |
91%
Epidural blood patch rate
Placebo group: 86%
Dose studied: 1 mgsingle dosen = 442025
No randomized trial result
7 results from other study designs.
5%
Secondary effects
Dose studied: 3 mg on D1 and 2 mg/d on D2 and D33 daysn = 1021989
No comparable result
7 randomized-trial results measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 27 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
University of Virginia100 participants29 Jan 2018 to 12 Mar 2019
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia · Lecithin Acyltransferase Deficiency
University of California, San Diego50 participantsFeb 2010 to Jul 2014
Development
United States Naval Medical Center, San Diego29 participantsAug 2010 to Apr 2014
Postdural Puncture Headache
13 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 23 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Clinuvel Pharmaceuticals Limited100 participantsMay 2007 to 9 Dec 2009
Erythropoietic Protoporphyria
Clinuvel Pharmaceuticals Limited93 participantsMay 2012 to Jul 2013
Erythropoietic Protoporphyria
Clinuvel Pharmaceuticals Limited74 participantsSept 2009 to May 2011
Erythropoietic Protoporphyria